Aethlon Medical Announces Compliance With Nasdaq Listing Criteria

SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that Nasdaq has formally notified the Company that it has demonstrated compliance with all applicable requirements for the continued listing of its common stock on The Nasdaq Capital Market, including the $2.5 million stockholders' equity requirement. As previously disclosed, the Nasdaq Hearings Panel required the Company to evidence compliance with the stockholders' equity requirement by October 31, 2017. As a result of the foregoing, the Nasdaq compliance matter has been closed.

About Aethlon Medical

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com

Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com

View original content:http://www.prnewswire.com/news-releases/aethlon-medical-announces-compliance-with-nasdaq-listing-criteria-300534099.html

SOURCE Aethlon Medical, Inc.